In recent trading session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw 1.96 million shares changing hands at last check today with its beta currently measuring 0.53. Company’s recent per share price level of $6.03 trading at -$0.18 or -2.90% at last check today assigns it a market valuation of $1.84B. That most recent trading price of IOVA’s stock is at a discount of -203.98% from its 52-week high price of $18.33 and is indicating a premium of 7.63% from its 52-week low price of $5.57. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.2 million shares which gives us an average trading volume of 8.01 million if we extend that period to 3-months.
For Iovance Biotherapeutics Inc (IOVA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Upright in the red during last session for losing -2.90%, in the last five days IOVA remained trading in the red while hitting it’s week-highest on Monday, 01/27/25 when the stock touched $6.03 price level, adding 7.23% to its value on the day. Iovance Biotherapeutics Inc’s shares saw a change of -18.51% in year-to-date performance and have moved -3.52% in past 5-day. Iovance Biotherapeutics Inc (NASDAQ:IOVA) showed a performance of -15.90% in past 30-days. Number of shares sold short was 61.98 million shares which calculate 7.04 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 49.75% to its recent value today. Analysts have been projecting 11.5 as a low price target for the stock while placing it at a high target of 17. It follows that stock’s current price would drop -90.71% in reaching the projected high whereas dropping to the targeted low would mean a loss of -90.71% for stock’s current value.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Statistics highlight that Iovance Biotherapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -30.93% of value to its shares in past 6 months, showing an annual growth rate of 34.92% while that of industry is 16.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -8.25% during past 5 years.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Insiders are in possession of 0.58% of company’s total shares while institution are holding 88.97 percent of that, with stock having share float percentage of 89.49%. Investors also watch the number of corporate investors in a company very closely, which is 88.97% institutions for Iovance Biotherapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at IOVA for having 25.95 million shares of worth $208.12 million. And as of 2024-06-30, it was holding 9.7478 of the company’s outstanding shares.
The second largest institutional holder is PERCEPTIVE ADVISORS LLC, which was holding about 25.93 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.7412 of outstanding shares, having a total worth of $207.98 million.
On the other hand, Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 8.72 shares of worth $52.41 million or 2.86% of the total outstanding shares. The later fund manager was in possession of 7.13 shares on Nov 30, 2024, making its stake of worth around $42.85 million in the company or a holder of 2.34% of company’s stock.
